Merz drops Obagi bet after Valeant raises bid
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals' revised bid to buy dermatology specialist Obagi Medical Products was too rich for Merz Pharma Group's blood, so the German company dropped its public offer to buy Obagi after Valeant raised its acquisition price to $24 per share.